«Ozanimod's ability to
inhibit brain atrophy promises patients a long and productive life, living with relapsing, remitting multiple sclerosis without disability,» said TSRI Professor of Molecular Medicine Hugh Rosen, Ph.D., M.D., co-inventor of ozanimod.